FIRE Funds Income Target ETF FIRI 深 滬
等待開盤 06-02 09:30:00 美东时间
18.9449
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 18.9449
- 總市值 123.14万
- 52周最高 19.115
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 17.6612
- 委 比 0.00%
- 總股本 6.50万
- 歷史最高 18.1637
- 量 比 0
- 振 幅 0.00%
- 歷史最低 17.7417
- 每 手 1
- 風險率 0.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Actuate Therapeutics Features Post-Hoc Efficacy And Biomarker Analyses From Randomized Phase 2 Study, Along With Clinical Data From Phase 2 Study Of Elraglusib In Combination With FFX And TGF-Β Inhibitor Losartan In mPDAC Patients, At 2026 ASCO
- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone- Patients with P53WT genomics
06-01 19:07
Cardiff Oncology Reveals Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib In First-Line RAS-Mutated mCRC
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that it will host an investor webcast featuring members of
05-22 05:06
Oncolytics Biotech Announces Its Data From REO 022 Trial In Metastatic Colorectal Cancer Shows 19.5-Month Median Duration Of Response In Second-Line KRAS-Mutant MSS mCRC Participants
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to activate innate
05-04 21:02
Cardiff Oncology To Present Updated Data From CRDF-004 In Participants With First-Line RAS-Mutated Metastatic Colorectal Cancer At 2026 American Society Of Clinical Oncology
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced it will present updated data from CRDF-004, a randomized
04-21 22:06
Caris Life Sciences Launches AI-Driven Pancreatic Cancer Signature To Guide First-Line Treatment In Pancreatic Ductal Adenocarcinoma
Caris AI Insights are proprietary and only available to Caris Life Sciences customersIRVING, Texas, March 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric,
03-09 20:39
Revolution Medicines outlines $1.6B–$1.7B 2026 operating expenses as RAS(ON) inhibitor trials expand
Earnings Call Insights: Revolution Medicines (RVMD) Q4 2025 Management View CEO Mark Goldsmith emphasized "substantial progress and growing momentum for our pioneering RAS(ON) inhibitor pipeline and o...
02-26 10:18
Pfizer's Braftovi Regimen Wins Complete FDA Nod For Colorectal Cancer Treatment
Pfizer stock rises after FDA fully approves Braftovi combo for metastatic colorectal cancer with BRAF V600E mutation.
02-26 02:22
Pfizer Announces Topline PFS Survival Results From Cohort 3, Separate Randomized Cohort Of Pivotal BREAKWATER Trial, Evaluating BRAFTOVI In Combination With Cetuximab And FOLFIRI In mCRC With BRAF V600E Mutation
BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in progression-free survival in BRAF V600E-mutant metastatic colorectal cancerResults reinforce potential of
02-17 19:48
Pfizer Reports BRAFTOVI Regimen Improves Progression-Free Survival in BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Reports BRAFTOVI Regimen Improves Progression-Free Survival in BRAF V600E-Mutant Metastatic Colorectal Cancer Pfizer Inc. announced positive topline results from Cohort 3 of the pivotal Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with cetuximab and FOLFIRI in pat
02-17 19:45
FDA Grants Fast Track Designation to Oncolytics Biotech's Pelareorep for KRAS-Mutant MSS Metastatic Colorectal Cancer
FDA Grants Fast Track Designation to Oncolytics Biotech's Pelareorep for KRAS-Mutant MSS Metastatic Colorectal Cancer Oncolytics Biotech Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to pelareorep in combination with bevacizumab (Avastin®) and FOL
02-04 21:50
